Is STTK or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Black Diamond Therapeutics N/A -30.18% -23.91%

Does the media favor STTK or BDTX?

In the previous week, Shattuck Labs had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Shattuck Labs and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Shattuck Labs' score of 0.46 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Black Diamond Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LRMR or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Black Diamond Therapeutics N/A -30.18% -23.91%

Does the media refer more to LRMR or BDTX?

In the previous week, Larimar Therapeutics had 6 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 9 mentions for Larimar Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Larimar Therapeutics' score of 0.61 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVCT or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% Black Diamond Therapeutics N/A -30.18% -23.91%

Does the media favor NVCT or BDTX?

In the previous week, Nuvectis Pharma had 5 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 8 mentions for Nuvectis Pharma and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Nuvectis Pharma's score of 0.58 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RCKT or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -69.61% -58.63% Black Diamond Therapeutics N/A -30.18% -23.91%

Does the media favor RCKT or BDTX?

In the previous week, Rocket Pharmaceuticals and Rocket Pharmaceuticals both had 3 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Rocket Pharmaceuticals' score of 1.22 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Black Diamond Therapeutics (BDTX) Competitors

$1.85 +0.10 (+5.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 +0.01 (+0.54%)

As of 07:02 PM Eastern

Compare

BDTX vs. STTK, LRMR, ENTA, NVCT, and RCKT

Should you buy Black Diamond Therapeutics stock or one of its competitors? MarketBeat compares Black Diamond Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Black Diamond Therapeutics include Shattuck Labs (STTK), Larimar Therapeutics (LRMR), Enanta Pharmaceuticals (ENTA), Nuvectis Pharma (NVCT), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical products" industry.

How does Black Diamond Therapeutics compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Shattuck Labs has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, indicating that its share price is 222% more volatile than the broader market.

Black Diamond Therapeutics' return on equity of -30.18% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, Shattuck Labs had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 4 mentions for Shattuck Labs and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Shattuck Labs' score of 0.46 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Black Diamond Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs currently has a consensus target price of $11.00, suggesting a potential upside of 58.50%. Black Diamond Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 440.54%. Given Black Diamond Therapeutics' higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Black Diamond Therapeutics has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	532.16	-$48.81M	-$0.63	N/A
Black Diamond Therapeutics	$70M	1.51	$22.37M	-$0.77	N/A

Summary

Black Diamond Therapeutics beats Shattuck Labs on 11 of the 16 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Larimar Therapeutics currently has a consensus price target of $13.17, suggesting a potential upside of 331.69%. Black Diamond Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 440.54%. Given Black Diamond Therapeutics' higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Black Diamond Therapeutics has higher revenue and earnings than Larimar Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Black Diamond Therapeutics	$70M	1.51	$22.37M	-$0.77	N/A

Black Diamond Therapeutics' return on equity of -30.18% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, Larimar Therapeutics had 6 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 9 mentions for Larimar Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Larimar Therapeutics' score of 0.61 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, indicating that its stock price is 222% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Larimar Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Black Diamond Therapeutics has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Black Diamond Therapeutics' return on equity of -30.18% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, Black Diamond Therapeutics had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 3 mentions for Black Diamond Therapeutics and 1 mentions for Enanta Pharmaceuticals. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Enanta Pharmaceuticals' score of 0.73 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Positive
Black Diamond Therapeutics	Positive

Enanta Pharmaceuticals presently has a consensus target price of $20.29, indicating a potential upside of 39.13%. Black Diamond Therapeutics has a consensus target price of $10.00, indicating a potential upside of 440.54%. Given Black Diamond Therapeutics' higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Black Diamond Therapeutics has higher revenue and earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	6.49	-$81.89M	-$2.59	N/A
Black Diamond Therapeutics	$70M	1.51	$22.37M	-$0.77	N/A

Enanta Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, suggesting that its share price is 222% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Enanta Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Nuvectis Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Nuvectis Pharma currently has a consensus price target of $39.00, suggesting a potential upside of 112.07%. Black Diamond Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 440.54%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Black Diamond Therapeutics has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Black Diamond Therapeutics	$70M	1.51	$22.37M	-$0.77	N/A

Black Diamond Therapeutics' return on equity of -30.18% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, Nuvectis Pharma had 5 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 8 mentions for Nuvectis Pharma and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Nuvectis Pharma's score of 0.58 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvectis Pharma has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, suggesting that its stock price is 222% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Nuvectis Pharma on 12 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Rocket Pharmaceuticals currently has a consensus target price of $8.88, suggesting a potential upside of 159.50%. Black Diamond Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 440.54%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.33
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rocket Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the broader market.

Black Diamond Therapeutics' return on equity of -30.18% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, Rocket Pharmaceuticals and Rocket Pharmaceuticals both had 3 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.33 beat Rocket Pharmaceuticals' score of 1.22 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
Black Diamond Therapeutics	$70M	1.51	$22.37M	-$0.77	N/A

Summary

Black Diamond Therapeutics beats Rocket Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDTX vs. The Competition

Export

Metric	Black Diamond Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$100.28M	$3.66B	$6.87B	$12.45B
Dividend Yield	N/A	2.20%	2.67%	6.16%
P/E Ratio	-2.40	20.90	27.51	24.87
Price / Sales	1.51	341.80	540.69	102.84
Price / Cash	3.32	143.77	48.53	58.59
Price / Book	0.94	8.75	11.01	6.54
Net Income	$22.37M	$23.81M	$3.57B	$336.70M
7 Day Performance	14.91%	3.64%	2.56%	3.31%
1 Month Performance	-16.67%	1.64%	0.89%	1.68%
1 Year Performance	-25.40%	69.47%	36.84%	31.96%

Black Diamond Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDTX Black Diamond Therapeutics	4.2381 of 5 stars	$1.85 +5.7%	$10.00 +440.5%	-25.5%	$100.28M	$70M	N/A	90	News Coverage
STTK Shattuck Labs	4.0987 of 5 stars	$5.24 +5.9%	$11.00 +109.9%	+702.4%	$379.57M	$1M	N/A	100	Short Interest Increase
LRMR Larimar Therapeutics	3.0395 of 5 stars	$3.66 +0.5%	$15.29 +317.6%	+5.6%	$378.13M	N/A	N/A	30	News Coverage Analyst Forecast
ENTA Enanta Pharmaceuticals	1.7795 of 5 stars	$13.37 +5.6%	$20.29 +51.7%	+93.5%	$368.13M	$65.32M	N/A	160
NVCT Nuvectis Pharma	2.3118 of 5 stars	$16.53 +19.6%	$39.00 +135.9%	+277.9%	$366.58M	N/A	N/A	8	News Coverage Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDTX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. STTK, LRMR, ENTA, NVCT, and RCKT

How does Black Diamond Therapeutics compare to Shattuck Labs?

Summary

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Summary

How does Black Diamond Therapeutics compare to Enanta Pharmaceuticals?

Summary

How does Black Diamond Therapeutics compare to Nuvectis Pharma?

Summary

How does Black Diamond Therapeutics compare to Rocket Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. STTK, LRMR, ENTA, NVCT, and RCKT

How does Black Diamond Therapeutics compare to Shattuck Labs?

Do institutionals and insiders hold more shares of STTK or BDTX?

Which has more risk and volatility, STTK or BDTX?

Is STTK or BDTX more profitable?

Does the media favor STTK or BDTX?

Do analysts prefer STTK or BDTX?

Which has stronger earnings & valuation, STTK or BDTX?

Summary

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Do insiders & institutionals hold more shares of LRMR or BDTX?

Do analysts prefer LRMR or BDTX?

Which has higher earnings and valuation, LRMR or BDTX?

Is LRMR or BDTX more profitable?

Does the media refer more to LRMR or BDTX?

Which has more risk & volatility, LRMR or BDTX?

Summary

How does Black Diamond Therapeutics compare to Enanta Pharmaceuticals?

Is ENTA or BDTX more profitable?

Does the media favor ENTA or BDTX?

Do analysts recommend ENTA or BDTX?

Do insiders and institutionals have more ownership in ENTA or BDTX?

Which has higher valuation & earnings, ENTA or BDTX?

Which has more risk & volatility, ENTA or BDTX?

Summary

How does Black Diamond Therapeutics compare to Nuvectis Pharma?

Do analysts recommend NVCT or BDTX?

Do institutionals & insiders have more ownership in NVCT or BDTX?

Which has preferable earnings and valuation, NVCT or BDTX?

Is NVCT or BDTX more profitable?

Does the media favor NVCT or BDTX?

Which has more volatility & risk, NVCT or BDTX?

Summary

How does Black Diamond Therapeutics compare to Rocket Pharmaceuticals?

Do analysts prefer RCKT or BDTX?

Do insiders and institutionals believe in RCKT or BDTX?

Which has more risk and volatility, RCKT or BDTX?

Is RCKT or BDTX more profitable?

Does the media favor RCKT or BDTX?

Which has stronger earnings & valuation, RCKT or BDTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools